Lymphocyte-depleting polyclonal antibodies can be used for induction immunosuppressive therapy for kidney transplantation. This strategy should be considered for renal transplant recipients at high risk of delayed graft function, which can predict acute rejection.
It is recommended by the American Society of Transplant Surgeons to include a biologic agent as part of the initial immunosuppressive induction regimen for kidney transplantation, with a nondepleting monoclonal antibody as the preferred first-line option.
Learn more about biologic agents for immunosuppression in kidney transplantation.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ron Shapiro. Fast Five Quiz: Immunosuppression for Kidney Transplantation - Medscape - Oct 22, 2021.